Related Experiment Videos
DNA methylation and cancer therapy.
1Department of Pharmacology and Therapeutics, McGill University, 3655 Sir William Promenade, Quebec H3G 1Y6, Montreal, Canada. mszyf@pharma.mcgill.ca
Summary
DNA methylation aberrations, including hypo- and hypermethylation, are hallmarks of cancer. This review explores their roles and proposes a unified hypothesis for improved anticancer therapy targeting DNA methylation machinery.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Vertebrate DNA methylation primarily occurs at CpG dinucleotides, with ~80% of CpGs methylated.
- Methylation patterns are cell-type specific, influencing gene expression and chromatin structure.
- Cancer exhibits aberrant DNA methylation: global hypomethylation, regional hypermethylation, and altered DNA methyltransferase expression.
Purpose of the Study:
- To review the roles of DNA methylation alterations in cancer.
- To propose a unified hypothesis on the interplay of DNA methyltransferases, hypomethylation, and hypermethylation in cancer.
- To discuss implications for anticancer therapy targeting DNA methylation.
Main Methods:
- Literature review of DNA methylation in cancer.
- Analysis of existing data on DNA methylation aberrations.
- Formulation of a unifying hypothesis based on current evidence.
Main Results:
- Cancer is characterized by global DNA hypomethylation and regional hypermethylation.
- DNA methyltransferase expression is often deregulated in cancer.
- Inhibiting DNA methylation for therapy may have adverse effects, like promoting metastasis.
Conclusions:
- A unified hypothesis is proposed to explain the coexistence of hypo- and hypermethylation in cancer.
- Understanding these complex methylation changes is crucial for developing effective anticancer therapies.
- Targeting DNA methylation machinery requires careful consideration of potential side effects.